Methanone, [2-amino-4-[3-(trifluoromethyl)phenyl]-3-thienyl]phenyl- manufacturers
- VPC171
-
- $30.00
-
2026-08-30
- CAS:1018830-99-3
- Purity: 99.78%
- Supply Ability: 10g
|
| | Methanone, [2-amino-4-[3-(trifluoromethyl)phenyl]-3-thienyl]phenyl- Basic information |
| Product Name: | Methanone, [2-amino-4-[3-(trifluoromethyl)phenyl]-3-thienyl]phenyl- | | Synonyms: | Methanone, [2-amino-4-[3-(trifluoromethyl)phenyl]-3-thienyl]phenyl-;VCP171;VPC171;(2-Amino-4-(3-(trifluoromethyl)phenyl)thiophen-3-yl)(phenyl)methanone;VCP171,Lamina II,AMPAR,Sprague-Dawley rats,Adenosine Receptor,P1 receptor,neuropathic pain,VCP-171,VPC171,inhibit,Inhibitor,A1R,VCP 171,neurons;(2-Amino-4-(3-(trifluoromethyl)phenyl)thiophen-3-yl)(phenyl)methanone , VCP171;VPC171, 10 mM in DMSO | | CAS: | 1018830-99-3 | | MF: | C18H12F3NOS | | MW: | 347.35 | | EINECS: | | | Product Categories: | | | Mol File: | 1018830-99-3.mol | ![Methanone, [2-amino-4-[3-(trifluoromethyl)phenyl]-3-thienyl]phenyl- Structure](CAS/20210305/GIF/1018830-99-3.gif) |
| | Methanone, [2-amino-4-[3-(trifluoromethyl)phenyl]-3-thienyl]phenyl- Chemical Properties |
| Boiling point | 507.0±50.0 °C(Predicted) | | density | 1.345±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 30 mg/ml,DMSO: 30 mg/ml,DMSO:PBS (pH 7.2) (1:6): 0.14 mg/ml,Ethanol: 10 mg/ml | | form | A crystalline solid | | pka | -1.73±0.14(Predicted) |
| | Methanone, [2-amino-4-[3-(trifluoromethyl)phenyl]-3-thienyl]phenyl- Usage And Synthesis |
| Uses | VCP171 is a potent adenosine A1 receptor (A1R) positive allosteric modulator (PAM). VCP171 is effective at decreasing excitatory synaptic currents in Lamina II of neuropathic pain model. VCP171 can be used for researching neuropathic pain[1]. | | Biological Activity | VCP171 is a positive allosteric modulator of adenosine A1 receptors (EC50 = 15.8 μM in a kinetic assay measuring agonist dissociation).1. It reduces AMPA receptor-mediated evoked excitatory postsynaptic currents (eEPSCs) in lamina I and lamina II neurons in a rat model of neuropathic pain (EC50s = 1.995 and 0.251 μM, respectively) to a greater extent than in sham control animals (EC50s = 2.512 and 0.631 μM, respectively).2 | | in vivo | VCP171 (10 μM) reduces AMPAR-mediated evoked excitatory postsynaptic current (eEPSCs) in lamina I cells in sham and nerve-injured animals; increases paired pulse ration in cells from sham control animals; is significantly more effective in Lamina II neurons from nerve-injured animals than sham controls[1]. | Animal Model: | Neurons from male Sprague-Dawley rats (5-6 weeks; performed a partial nerve ligation (PNL) of the left sciatic nerve to create neuropathic pain model)[1] | | Dosage: | 10 μM | | Administration: | 0-30 min | | Result: | Reduced AMPAR-mediated evoked excitatory postsynaptic current (eEPSCs) in Lamina I cells in sham (13±2%, n=7 cells) and nerve-injured animals (24±4%, n=8 cells) compared with predrug controls; increased paired pulse ration in cells from sham control animals; was significantly more effective in Lamina II neurons from nerve-injured animals than sham controls. |
| | IC 50 | A1R | | storage | Store at -20°C | | References | 1.Aurelio, L., Figler, H., Flynn, B.L., et al.5-Substituted 2-aminothiophenes as A1 adenosine receptor allosteric enhancersBioorg. Med. Chem.16(3)1319-1327(2008)
2.Imlach, W.L., Bhola, R.F., May, L.T., et al.A positive allosteric modulator of the adenosine A1 receptor selectively inhibits primary afferent synaptic transmission in a neuropathic pain modelMol. Pharm.88(3)460-468(2015) |
| | Methanone, [2-amino-4-[3-(trifluoromethyl)phenyl]-3-thienyl]phenyl- Preparation Products And Raw materials |
|